Abiopharma

OUTLOOK THERAPEUTICS, INC. (OTLK) Reports the reporting period Financial Results OUTLOOK THERAPEUTICS, INC. (OTLK) announced its financial results for the period ending the reporting period. Key Financial Highlights:

• Revenue: $62
• Net Income: Not disclosed
• EPS: Not disclosed
• Cash and equivalents: $62
  • targeting development of our product candidates. The total addressable market opportunity for our product candidates will ultimately depend upon a number of factors including the diagnosis and treatment criteria included in the final label, if approved for sale in specified indications, acceptance by the medical community, patient access and product pricing and reimbursement. Incidence and prevalence estimates are frequently based on information and assumptions that are not exact and may not be appropriate, and the methodology is forward-looking and speculative. The process we have used in developing an estimated incidence and prevalence range for the indications we are targeting has involved collating limited data from multiple sources. Accordingly, the incidence and prevalence estimates included in our other filings with the Securities and Exchange Commission, or the SEC, should be viewed with caution. Further, the data and statistical information used in our other filings with the SEC, including estimates derived from them, may differ from information and estimates made by our competitors or from current or future studies conducted by independent sources. If the commercial launch of LYTENAVA is delayed or unsuccessful, or if sales of LYTENAVA do not meet the levels currently expected, we may face costs related to excess inventory or unused capacity at our manufacturing facilities and at the facilities of third parties or our collaborators. If the commercial launch of LYTENAVA is delayed or unsuccessful, sales of LYTENAVA do not meet the levels currently expected, LYTENAVA is discontinued, the launch of new indications for our marketed products or new product candidates is delayed or does not occur, or if such products are launched and the launch is unsuccessful or the product is subsequently recalled or marketing approval is rescinded, we may have to absorb one hundred percent of related overhead costs and inefficiencies, as well as similar costs of third-party contract manufacturers performing services for us. In addition, if we or our future collaborators experience excess inventory, it may be necessary to write down or write off such excess inventory or incur an impairment charge with respect to the facility where such product is manufactured, which could adversely affect our operating results. Risks Related to Our Reliance on Third Parties We depend on third parties for the commercialization of LYTENAVA. Failure to commercialize in the relevant markets could harm our business and operating results. We continue to pursue discussions for the licensing and/or co-development rights to LYTENAVA outside of the US. We may not be successful in reaching agreements with such parties on terms that are as favorable to the Company as we would anticipate. We do not have in place any licensing agreements for commercialization of LYTENAVA and have only licensed LYTENAVA to our PRC joint venture, for commercialization in greater China. Our current arrangements are for our inactive biosimilar product candidates, and aside from one US arrangement for ONS-3010